Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

Journal of Clinical Oncology - United States
doi 10.1200/jco.2008.21.6630
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

P3-027Liver Cirrhosis Associated With Paclitaxel and Bevacizumab Combination Therapy in a Metastatic Breast Cancer Patient

Annals of Oncology
MedicineOncologyHematology
2018English

Caveolin-1 Expression Predicts Efficacy of Weekly Nab-Paclitaxel Plus Gemcitabine for Metastatic Breast Cancer in the Phase II Clinical Trial

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

The Results of a Study of Chemotherapy With Bevacizumab, Oxaliplatin and Paclitaxel in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
2017English

A Phase 2 Randomised Study of Veliparib Plus FOLFIRI±bevacizumab Versus Placebo Plus FOLFIRI±bevacizumab in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

A Randomized Phase 2 Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer

Cancer
Cancer ResearchOncology
2010English

Quality-Adjusted Survival With Nab -Paclitaxel vs Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis

Clinical Breast Cancer
Cancer ResearchOncology
2018English

A Phase II Trial of Erlotinib in Combination With Bevacizumab in Patients With Metastatic Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2008English

Paclitaxel in Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
1998English

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy